ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / STTK / forecast
NGNE (36) EVO (47) GERN (28) DRUG (46) ⌘ Pro Terminal →

Shattuck Labs Inc. (STTK) 12-Month Stock Forecast & Price Target Cone

$5.32 -4.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.27

Shattuck Labs Inc. (STTK) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $558.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on STTK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is STTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Shattuck Labs Inc. (NASDAQ: STTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $5.32 (-4.32% 1D, market cap $558.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, STTK ranks #825 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does STTK compare to NGNE and EVO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STTK carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NGNE (Neurogene Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $551.3M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, STTK leads on earnings multiple (N/A) while GERN leads on capital efficiency (-20.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for STTK?
▼

Per STTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680367), Shattuck Labs Inc. generated $1.0M in revenue (-82.5% YoY), -$48.8M in net income, and -$40.0M in free cash flow against $91.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.27 (-0.97%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (8)Whales (5)SEC (8)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$9 Bull$5 Base$4 Bear
📬 FREE STTK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STTK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY STTK SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$5.49+6.4% Next Q
Q2 (-2Q)
34
Grade E$5.84-1.2% Next Q
Q3 (-1Q)
32
Grade E$5.77-7.8% Next Q
Current
29
Grade E$5.32-9.8% Hist 90D α
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a STTK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While STTK currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.20) and Max Pain ($5.59) forces dealer call-delta covering toward $8.75.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $STTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “STTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your STTK Position Size: $10,000

Shares at $5.32: 1879.7 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $3.61
$6,786
$-3,214 (-32.1%)
12M Consensus BaseTarget $4.63
$8,703
$-1,297 (-13.0%)
12M Bull Case BreakoutTarget $8.75
$16,447
+$6,447 (+64.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$574%A
Goldman SachsSector Coverage LeadUNDERPERFORM$869%B
JP MorganUS Large-Cap ResearchSELL$458%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STTK)

  • ✓Walkthrough of STTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
STTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.12%🛡️ HOLDING TREND SUPPORT
2026-11-03O $5.72H $5.72L $5.32C $5.32VOL 951.5K
RES: $8.90SUP: $5.00SMA50: $6.20SMA200: $6.05
$8.49$7.09$5.69$4.29$2.90RES $8.90SUP $5.00$5.322026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STTK Butterfly Map → + Track STTK →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -82.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on STTK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STTK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for STTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STTK)

Health Care Rank #825 of 1015 ⚔️ NGNE vs STTK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STTK vs. NGNE, EVO, GERN, DRUG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Shattuck Labs Inc. (STTK) ranks #825 by composite RQD confidence (29/100, grade E) and #423 by equity capitalization ($558.0M). Within this direct 5-issuer industry benchmark cohort, STTK leads on earnings valuation at N/A trailing P/E, while GERN leads on capital efficiency and profitability with -20.2% ROIC and — gross margin. EVO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with STTK at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
STTK ACTIVE
Shattuck Labs Inc.
E 29/100 — — -35.0% -4.32% $558.0M Benchmark Subject
NGNE
Neurogene Inc.
D- 36/100 — — -35.0% -3.41% $551.3M /ngne-vs-sttk →
EVO
Evotec SE
D 47/100 — — — -0.65% $544.3M /evo-vs-sttk →
GERN
Geron Corporation
E 28/100 — — -20.2% +3.88% $574.6M /gern-vs-sttk →
DRUG
Bright Minds Biosciences Inc.
D 46/100 — — — -52.35% $539.9M /drug-vs-sttk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680367 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shattuck Labs Inc. (STTK) reported GAAP revenue of $1.0M (-82.5% vs. FY2024 revenue of $5.7M , and -39.6% cumulative change since FY2023) , GAAP net income of -$48.8M, operating cash flow of -$39.9M, and free cash flow of -$40.0M (+34.0% YoY). On the balance sheet, STTK closed FY2025 with $91.0M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.0M -$48.8M -$39.9M -$40.0M $91.0M —
FY2024 (FY) 2024-12-31 $5.7M -$75.4M -$60.5M -$60.6M $91.0M —
FY2023 (FY) 2023-12-31 $1.7M -$87.3M -$81.2M -$81.2M — —

3. STTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Shattuck Labs Inc. (NASDAQ: STTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $5.32 (-4.32% 1D, market cap $558.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, STTK ranks #825 in composite RQD confidence.

How does STTK compare to NGNE and EVO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STTK carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NGNE (Neurogene Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $551.3M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, STTK leads on earnings multiple (N/A) while GERN leads on capital efficiency (-20.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for STTK?

Per STTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680367), Shattuck Labs Inc. generated $1.0M in revenue (-82.5% YoY), -$48.8M in net income, and -$40.0M in free cash flow against $91.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is STTK trading relative to its 50-day, 200-day, and 52-week technical levels?

STTK last traded at $5.32 (-4.32% on volume of 651,690 shares), positioning the stock -14.19% below its 50-day simple moving average ($6.20) and -12.07% below its 200-day simple moving average ($6.05). Across its 52-week range of $1.72 to $8.33, STTK sits at the 54.5% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.65 to $5.99).

Direct Sub-Reports: STTK RQD Cockpit STTK 12M Forecast STTK Earnings & Move STTK Dividends & DRIP STTK Insiders & 13F STTK Whale Options STTK Profit Sankey STTK News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

STTK — Shattuck Labs Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Shattuck Labs Inc. (STTK) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $5.32 (-4.32% 1D, market capitalization $558.0M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -6.96%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Shattuck Labs Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..6B. Per the market data, revenue reported for FY 2025 was $1.0M, indicating minimal current commercial revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Shattuck Labs Inc. (STTK) reported $1.0M in annual revenue (up from $5.7M in FY2024, -82.5% YoY) and -$48.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.7M revenue, -$87.3M net income) through FY2025, STTK scaled operating cash flow to -$39.9M and free cash flow to -$40.0M, backed by $91.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.96% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.72 – $8.33 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain is NONE, with no upstream or downstream dependencies and no proprietary signals recorded. Sector correlations and 2nd-order bottlenecks are — Investors should monitor how the company's cash position, which the SEC financials show at $54.2M against a -$40.0M FCF in FY 2025, interacts with future clinical or partnership milestones, though no such linkage is documented in the source data.

  • Key Question #1: Can STTK sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.0M and free cash flow of -$40.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is STTK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

STTK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Shattuck Labs Inc. (STTK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to STTK Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

STTK Bull vs. Bear Conversation Board — What's Your Call at $5.32?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STTK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on STTK:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $6.56 (+18.0%)
📌 Pinned Debate

UBS initiated coverage at Buy with a $17 price target, and Leerink Partners kept its Buy rating.

Here is why I am bullish on STTK here at $5.56: UBS initiated coverage at Buy with a $17 price target, and Leerink Partners kept its Buy rating.. Compare STTK's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $5.28 are getting bought.

RetailWhale_TX 🐂 BULL

@ShortSeller_Dan Shorting a 5/20 institutional whale-flow stock at $5.56 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $4.67 (-16.0%)
Spot @ $5.56

Operating losses of -$51.5M and negative free cash flow of -$40.0M in FY 2025 against $1.0M of revenue.

Careful chasing STTK at $5.56. Operating losses of -$51.5M and negative free cash flow of -$40.0M in FY 2025 against $1.0M of revenue.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $4.67 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%